Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18558256 | 0.93 | VNN1 (0.39) | VNN1GRM5MAPK1 | |
| SCHEMBL18558203 | 0.88 | VNN1 (0.39) | VNN1GRM5IRAK4 | |
| SCHEMBL18558081 | 0.88 | MAPK1 (0.37) | VNN1GRM5MAPK1 | |
| SCHEMBL18558451 | 0.87 | MAPK1 (0.36) | VNN1GRM5MAPK1 | |
| SCHEMBL18558338 | 0.85 | GPR139 (0.38) | VNN1GRM5MAPK1 | |
| SCHEMBL18558452 | 0.84 | GPR139 (0.35) | VNN1GRM5MAPK1 | |
| SCHEMBL19362692 | 0.83 | GRM5 (0.41) | VNN1GRM5 | |
| SCHEMBL18558515 | 0.83 | VNN1 (0.38) | VNN1MAPK1 | |
| SCHEMBL18557827 | 0.83 | CHRNA1 (0.35) | VNN1 | |
| SCHEMBL18558233 | 0.83 | MAPK1 (0.38) | VNN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | VNN1 2342/4885GRM5 1418/4885MAPK1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.